4 - FEMASYS INC (0001339005) (Issuer)

4 - FEMASYS INC (0001339005) (Issuer)

4 - FEMASYS INC (0001339005) (Issuer)

4 - FEMASYS INC (0001339005) (Issuer)

4 - FEMASYS INC (0001339005) (Issuer)

3 - FEMASYS INC (0001339005) (Issuer)

4 - FEMASYS INC (0001339005) (Issuer)

4 - FEMASYS INC (0001339005) (Issuer)

4 - FEMASYS INC (0001339005) (Issuer)

4 - FEMASYS INC (0001339005) (Issuer)

ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the American Association of Gynecologic Laparoscopists (AAGL) 2024 Annual Global Conference, being held November 16-19 in New Orleans, Louisiana. The Company will be showcasing its product candidate in late-stage clinical development, FemBloc®, as well as its other commercially available solutions at booth #902. About AAGL AAGL is the largest medical society focused on gynecol

ATLANTA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the United States Patent and Trademark Office ("USPTO") issued U.S. Patent No. 12,12796 covering FemBloc® permanent birth control. This further strengthens Femasys' intellectual property position and coverage for FemBloc, the Company's leading therapeutic product candidate. The issued patent has an anticipated expiration in 2039 at the earliest. Femasys intends to continue to prosecute additional patent applicati

ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces a partnership with Boston IVF, one of the largest providers of fertility services in the U.S. Boston IVF will provide the Company's FemaSeed intratubal insemination product as an infertility treatment option to patients throughout its network of locations in the U.S. "We are elated to welcome Boston IVF, a prominent conglomerate in the infertility space, to our growing group of providers offering our FemaSeed treatm

ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024. Event: Fireside Chat at 2024 Maxim Healthcare Virtual Summit  Date: Thursday, October 17, 2024  Time: 11:00 AM ET  Webcast: h

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception

ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the onboarding of the first infertility medical clinic customers to offer its FemaSeed infertility treatment to patients in California and Florida. "Femasys has begun partnering with infertility centers across the United States, enabling them to offer FemaSeed to their patients. We are excited to welcome Reproductive Fertility Center and Palm Beach Fertility Center as our first customers," said Femasys CEO Kathy Le

ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has secured strategic distribution partnerships for its CE-marked products, including FemaSeed® and FemVue® in Spain. Comercial Medico Quirurigca, SA (CMQ) will distribute the products in northern Spain and Durgalab will distribute them in the south. Spain is the first EU country where the Company has identified distributors and began marketing its products. Kathy-Lee Sepsick, Femasys Founder and C

ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for FemChec®, an innovative diagnostic solution for checking the fallopian tubes, designed for controlled delivery of contrast for confirmation of tubal status. Kathy-Lee Sepsick, Femasys Founder and CEO commented, "FemChec is an essential part of our suite of women's health products, as it fortifies our position to

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society's (CFAS) 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26. Kathy-Lee Sepsick, Femasys Founder and CEO commented, "This is an important opportunity to connect with practitioners whose patients and clients would benefit from our suit

JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

8-K/A - FEMASYS INC (0001339005) (Filer)

10-Q - FEMASYS INC (0001339005) (Filer)

8-K - FEMASYS INC (0001339005) (Filer)

8-K - FEMASYS INC (0001339005) (Filer)

8-K - FEMASYS INC (0001339005) (Filer)

8-K - FEMASYS INC (0001339005) (Filer)

8-K - FEMASYS INC (0001339005) (Filer)

8-K - FEMASYS INC (0001339005) (Filer)

10-Q - FEMASYS INC (0001339005) (Filer)

8-K - FEMASYS INC (0001339005) (Filer)

ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) --  Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended June 30, 2024 and provides a corporate update. Corporate Highlights from 2Q 2024 to date Company received European Union Medical Device Regulation (EU MDR) certification and CE Mark for four of its women's health products, providing regulatory approval to begin marketing in the European Union. Further, it serves as independent validation of F

-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2024 and provides a corporate update. Corporate Highlights from 1Q 2024 to date Company announced positive topline data from pivotal trial for FDA-cleared FemaSeed® for the treatment of infertility.Company ann

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update. Corporate Highlights from 4Q 2023 to date Company announced positive topline data from pivotal trial for FDA-cleared FemaSeed® for the treatment of infertilityFollowing FDA clearance of FemaSeed, the Company's revolutionary approach to artificial insemination, Femasys announced completion of enrollment in pivotal trial in support

New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv

 - 510(k) product clearance gained for lead product, FemaSeed potentially allowing sooner-than-expected product commercialization - - Patient enrollment has commenced in landmark, pivotal FINALE trial for lead product candidate, FemBloc®, with academic sites enrolling trial participants - - Raised $11.3 million extending cash runway due to the exercise of warrants and sale of shares under its at-the-market facility - ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a leading late-clinical stage product cand

- 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which underscored the importance of potential reproductive health options like Femasys' FemBloc® for permanent birth control and FemaSeed® for infertility - The commercial launches of FemCath™ and FemCerv® broaden options for women while Femasys continues advancing development of its lead clinical programs FemBloc and FemaSeed® ATLANTA, March 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financ

--FemaSeed® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- --Company remains on track to file an Investigational Device Exemption (IDE) for a pivotal trial to support a Pre-Market Authorization (PMA) for FemBloc® in Q1 2023-- --FemCerv® now commercially available with FemCath™ launch expected by year-end-- ATLANTA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the third quarter and nine mon

Continued focus and progress with FemaSeed® and FemBloc® biomedical product candidates in developmentFemCerv® and FemCath™ commercial availability expected by year-end ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the second quarter and six months ended June 30, 2022 and provided a corporate update. "The decision this past quarter announcing the overturn of the landmark Roe v. Wade case underscores the importance for women to have access to

- Furthers advancement of much-needed minimally invasive technologies for underserved areas of women's health with pending commercialization of products, FemCerv® and FemCath™ expected by year-end - Continued progress with FemaSeed and FemBloc biomedical product candidates in development ATLANTA, May 11, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the first quarter ended March 31, 2022. "We are adding two approved products to our commercial portfolio as

SC 13D - FEMASYS INC (0001339005) (Subject)

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining more than 300 points on Thursday. The Dow traded up 0.87% to 39,171.26 while the NASDAQ fell 0.65% to 17,745.523. The S&P 500 also fell, dropping, 0.14% to 5,479.13. Check This Out: Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday Leading and Lagging SectorsEnergy shares jumped by 2% on Thursday. In trading on Thursday, information technology shares fell by 1.1%. Top Headline The EIA said stocks of crude oil in the U.S. declined by 2.547 million barrels in the week ending June 14, compared to market estimates of a 2.800 million barrels decline. Equities Trading

Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA

Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) stock rose 36.83% to $5.67. The market value of their outstanding shares is at $402.2 million. Femasys (NASDAQ:FEMY) stock increased by 28.27% to $1.23. The market value of their outstanding shares is at $27.2 million. SeaStar Medical Holding (NASDAQ:ICU) shares rose 18.68% to $4.89. The market value of their outstanding shares is at $15.2 million. Nanoviricides (AMEX:NNVC) shares rose 17.68% to $1.93. The company's market cap stands at $22.8 million. CASI Pharmaceuticals (NASDAQ:CASI) sha

U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.17% to 38,898.96 while the NASDAQ rose 0.01% to 17,864.13. The S&P 500 also rose, gaining, 0.09% to 5,491.81. Check This Out: Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday Leading and Lagging SectorsEnergy shares jumped by 1.5% on Thursday. In trading on Thursday, real estate shares fell by 0.2%. Top Headline Shares of Accenture Plc (NYSE:ACN) gained around 7% during Thursday's session after the company reported third-quarter fiscal 2024 results. The company posted sales of $

In the preceding three months, 4 analysts have released ratings for Femasys (NASDAQ:FEMY), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 Analysts have set 12-month price targets for Femasys, revealing an average target of $12.5, a high estimate of $13.00, and a low estimate of $12.00. Marking an increase of 4.17%, the current average sur

HC Wainwright & Co. analyst Emily Bodnar reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $13 price target.

Femasys Inc (NASDAQ:FEMY) is a biomedical company focused on women’s healthcare. The company, with a market capitalization of $22.50 million as of data from Benzinga Pro on 17 June, went public in June 2021. In an emailed interview with Benzinga, Kathy Lee-Sepsick, the founder & CEO of Femasys, said, “I considered permanent birth control but found the available options too risky.” Femasys’ commercially available products are: FemaSeed: A form of artificial insemination where sperm is delivered directly and safely into the fallopian tube FemVue: A contrast-generating device for ultrasound evaluation. FemCath: A delivery catheter for fallopian tube and uterine cavity eva

HC Wainwright & Co. analyst Emily Bodnar reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $13 price target.

ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

-- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a contin

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of James Liu, M.D., as Chief Medical Officer. Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®. "With an exciting product pipeline and a culture focused on execution of the development and commercialization of differentiated women's

-- Keith Kendall former President, COO and CFO of drug delivery company, Aquestive Therapeutics and Alistair Milnes COO of biotechnology company, Bicycle Therapeutics both join Femasys' Board of Directors -- ATLANTA, June 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has appointed Mr. Keith J. Kendall and Mr. Alistair Milnes to its board of directors. Messrs. Kendall and Milnes will be replacing Mr. John Dyett, who currently serves as Co-CEO of Salem Partners, LLC and Sale

ATLANTA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of Christine Thomas, RAC, as senior vice president of regulatory and clinical affairs, effective October 10, 2022. Ms. Thomas has over 20 years of successful leadership in regulatory and clinical affairs, including global strategy development and operations, as well as executive responsibility for medical device companies such as GE Healthcare, Boston Scientific, Smiths Medical, and RTI Surgical. Ms. Thomas

-- Seasoned financial executive with 25 years of experience leading public and private biotech companies throughout various stages -- ATLANTA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of Dov Elefant to chief financial officer (CFO), to be effective February 28, 2022. Mr. Elefant has 25 years of financial management experience at both public and private biopharmaceutical companies. "I am incredibly excited to bring Dov on board, not only because of his es

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer. Dr. Evantash brings over two decades of industry experience in medical and clinical affairs to Femasys, having previously served as chief medical officer of Alydia Health and vice president of medical affairs at Hologic, Inc., both medical technology